Login / Signup
Is BTKi or BCL2i preferable as first novel therapy in patients with CLL? The case for BCL2i.
John Francis Seymour
Published in:
Blood advances (2022)
Keyphrases
</>
stem cells
bone marrow
cell therapy
smoking cessation